Gastric Cancer

, Volume 8, Issue 4, pp 249–252 | Cite as

The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein

  • Christine Rebischung
  • Raphaëlle Barnoud
  • Laetitia Stéfani
  • Jean-Luc Faucheron
  • Mireille Mousseau
Case report


The c-erbB-2 protein is overexpressed in 7% of gastric cancer cases, suggesting that anti-c-erbB-2 antibody therapy (trastuzumab; Herceptin) could be used. We report here a 28-year-old woman with metastatic gastric cancer overexpressing c-erbB-2 (3 + strong membrane staining on immunohistochemistry) who was treated with trastuzumab in combination with chemotherapy. A complete response was obtained with a combination of trastuzumab and oxaliplatin and was maintained with trastuzumab alone for 18 months. The patient relapsed and chemotherapy (capecitabine, docetaxel) was combined with the anti-c-erbB-2 antibody. The patient survived for 4 years with metastatic disease controlled for 2 years by immunochemotherapy. We conclude that the combination of trastuzumab and chemotherapy is efficient in the treatment of metastatic gastric carcinoma with overexpression of the c-erbB-2 protein.

Key words

Gastric cancer c-erbB-2 protein Anti-EGF antibody Trastuzumab 


  1. 1.
    Slamon, DJ, Godolphin, W, Jones, LA, Holt, JA, Wong, SG, Keith, DE,  et al. 1989Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience24470712PubMedGoogle Scholar
  2. 2.
    Sakai, K, Mori, S, Kawamoto, T, Taniguchi, S, Kobori, O, Morioka, Y,  et al. 1986Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomasJ Natl Cancer Inst77104752PubMedGoogle Scholar
  3. 3.
    Takehana, T, Kunitomo, K, Kono, K, Kitahara, F, Iizuka, H, Matsumoto, Y,  et al. 2002Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assayInt J Cancer988337CrossRefPubMedGoogle Scholar
  4. 4.
    Ravdin, PM, Chamness, GC 1995The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers — a reviewGene1591927CrossRefPubMedGoogle Scholar
  5. 5.
    Allgayer, H, Babic, R, Gruetzner, KU, Tarabichi, A, Schildberg, FW, Heiss, MM 2000C-erbB-2 is of independant prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systemsJ Clin Oncol1822019PubMedGoogle Scholar
  6. 6.
    Nakajima, M, Sawada, H, Yamada, Y, Watanabe, A, Tatsumi, M, Yamashita, J,  et al. 1999The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomasCancer851894902PubMedGoogle Scholar
  7. 7.
    Mizutani, T, Onda, M, Tokunaga, A, Yamanaka, N, Sugisaki, Y 1993Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancerCancer7220838PubMedGoogle Scholar
  8. 8.
    Vogel, CL, Cobleigh, MA, Tripathy, D, Gutheil, JC, Harris, LN, Fehrenbacher, L,  et al. 2002Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol2071926CrossRefPubMedGoogle Scholar
  9. 9.
    Tanner, M, Hollmen, M, Juntilla, TT, Kapanen, AI, Tommola, S, Soini, Y,  et al. 2005Amplification of Her-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumabAnn Oncol162738CrossRefPubMedGoogle Scholar
  10. 10.
    Louvet, C, Andre, T, Tigaud, JM, Gamelin, E, Douillard, JY, Brunet, R,  et al. 2002Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patientsJ Clin Oncol2045438PubMedGoogle Scholar
  11. 11.
    Evans, TR, Pentheroudakis, G, Paul, J, McInnes, A, Blackie, R, Raby, N,  et al. 2002A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinomaAnn Oncol13146978CrossRefPubMedGoogle Scholar
  12. 12.
    Slamon, DJ, Leyland-Jones, B, Shak, S, Fuchs, H, Paton, V, Bajamonde, A,  et al. 2001Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med34478392CrossRefPubMedGoogle Scholar
  13. 13.
    Burstein, HJ, Kuter, I, Campos, SM, Gelman, RS, Tribou, L, Parker, LM,  et al. 2001Clinical activity of trastuzumab and vinorelbine in women with Her2-overexpressing metastatic breast cancerJ Clin Oncol19272230PubMedGoogle Scholar
  14. 14.
    Webb, A, Cunningham, D, Scarffe, JH, Harper, P, Norman, A, Joffe, JK,  et al. 1997Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancerJ Clin Oncol1517Google Scholar

Copyright information

© International and Japanese Gastric Cancer Association 2005

Authors and Affiliations

  • Christine Rebischung
    • 1
  • Raphaëlle Barnoud
    • 2
  • Laetitia Stéfani
    • 1
  • Jean-Luc Faucheron
    • 3
  • Mireille Mousseau
    • 1
  1. 1.Department of Oncology and HaematologyUniversity HospitalFrance
  2. 2.Department of AnatomopathologyUniversity Hospital of GrenobleGrenobleFrance
  3. 3.Department of SurgeryUniversity of GrenobleGrenobleFrance

Personalised recommendations